<DOC>
	<DOCNO>NCT02729168</DOCNO>
	<brief_summary>An open label , non-comparative bridging study evaluate safety Rabies vaccine INDIRAB® Healthy Vietnamese volunteer age 5 year old .</brief_summary>
	<brief_title>Safety Study Rabies Vaccine INDIRAB® Five Doses ( 0.5ml ) Post Exposure Administered Intramuscularly</brief_title>
	<detailed_description>The trial bridging study evaluate safety Rabies vaccine INDIRAB® Five Doses ( 0.5 ml ) post exposure administer Intramuscularly healthy Vietnamese Volunteer Aged 5 year old . 120 subject enrol Cho Gao district , Tien Giang province , 100 adult ( ≥15 year old ) 20 child ( 5- &lt; 15 year old ) . These subject receive 5 dos ( 0.5ml ) INDIRAB® D0 , 3 , 7 , 14 28 . The frequency , rate severity immediate adverse event ( AE ) within 30 minute vaccination , solicit unsolicited AE within 7 day vaccination , frequency rate serious adverse event ( SAE ) within 35 day first vaccination record evidence INDIRAB® safety assessment . The subject include trial would representative population Vietnam . The protocol review approved Institutional Review Board Pasteur Institute Ho Chi Minh City Vietnam Ministry Health - Independent Ethics Committee Vietnam Minister Health .</detailed_description>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female age 5 year old . Women childbearing age must use appropriate method contraception . 2 . Subjects sign write consent form participate study . With subject age 5 18 year old , parents/legal representative sign write consent form child participate study . 3 . Subject give voluntary comply study requirement . 1 . Subjects atopic allergy severe allergy component vaccine . 2 . Subjects mental illness , mental retardation . 3 . Subjects severe acute chronic disease may affect safety ( eg : hepatobiliary disease , kidney disease , diabetes , hypertension… ) . 4 . Subjects receive rabies vaccine . 5 . Subjects hemophilia receive treatment anticoagulant , increased risk serious bleed intramuscular injection . 6 . Subjects receive vaccine within 28 day INDIRAB® vaccination , another vaccination schedule study . 7 . Pregnant lactating woman . 8 . Subjects participate , participate , go participate clinical trial period study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Rabies</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>INDIRAB</keyword>
	<keyword>Vietnam</keyword>
</DOC>